Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

Virchows Archiv

Volumn 459, Issue 2, 2011, Pages 129-139

  Quint, Karl ^a,b   Agaimy, Abbas ^b   Di Fazio, Pietro ^a   Montalbano, Roberta ^a   Steindorf, Claudia ^b   Jung, Rudolf ^b,c   Hellerbrand, Claus ^c   Hartmann, Arndt ^b   Sitter, Helmut ^a   Neureiter, Daniel ^d   Ocker, Matthias ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Correlation analysis; Expression analysis; Hepatocellular carcinoma; Histone deacetylases; Overall survival; Tissue microarray

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 7; KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CARCINOMA, HEPATOCELLULAR; FEMALE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052417803     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1103-0     Document Type: Article

References (32)

1. FX Bosch J Ribes R Cleries M Diaz 2005 Epidemiology of hepatocellular carcinoma Clin Liver Dis 9 2 191 211 15831268 10.1016/j.cld.2004.12.009
2. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 9399 1907 1917 14667750 10.1016/S0140-6736(03)14964-1 (Pubitemid 37518510)
3. K Okamoto D Neureiter M Ocker 2009 Biomarkers for novel targeted therapies of hepatocellular carcinoma Histol Histopathol 24 4 493 502 19224452 1:CAS:528:DC%2BD1MXltFCntro%3D
4. TF Greten F Korangy MP Manns NP Malek 2009 Molecular therapy for the treatment of hepatocellular carcinoma Br J Canc 100 1 19 23 10.1038/sj.bjc. 6604784 1:CAS:528:DC%2BD1MXjt1Sgsg%3D%3D
5. RS Finn 2010 Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Canc Res 16 2 390 397 10.1158/1078-0432.CCR-09-2084 1:CAS:528:DC%2BC3cXktF2qsb0%3D
6. M Ocker R Schneider-Stock 2007 Histone deacetylase inhibitors: signalling towards p21cip1/waf1 Int J Biochem Cell Biol 39 7-8 1367 1374 17412634 10.1016/j.biocel.2007.03.001 1:CAS:528:DC%2BD2sXnslWltLk%3D (Pubitemid 47031035)
7. M Ocker 2010 Deacetylase inhibitors-focus on non-histone targets and effects World J Biol Chem 1 5 55 61 21540990 10.4331/wjbc.v1.i5.55
8. P Di Fazio R Schneider-Stock D Neureiter K Okamoto T Wissniowski S Gahr K Quint M Meissnitzer B Alinger R Montalbano G Sass B Hohenstein EG Hahn M Ocker 2010 The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis Cell Oncol 32 4 285 300 20208142
9. S Gahr G Peter TT Wissniowski EG Hahn C Herold M Ocker 2008 The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines Oncol Rep 20 5 1249 1256 18949429 1:CAS:528:DC%2BD1cXhsVaqtr3P
10. M Ocker A Alajati M Ganslmayer S Zopf M Luders D Neureiter EG Hahn D Schuppan C Herold 2005 The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells J Canc Res Clin Oncol 131 6 385 394 10.1007/s00432-004-0664-6 1:CAS:528: DC%2BD2MXjs1OlsLY%3D (Pubitemid 40674624)
11. W Weichert 2009 HDAC expression and clinical prognosis in human malignancies Canc Lett 280 2 168 176 10.1016/j.canlet.2008.10.047 1:CAS:528:DC%2BD1MXmsF2jt70%3D
12. FR Fritzsche W Weichert A Roske V Gekeler T Beckers C Stephan K Jung K Scholman C Denkert M Dietel G Kristiansen 2008 Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer BMC Canc 8 381 10.1186/1471-2407-8-381
13. M Ouaissi I Sielezneff R Silvestre B Sastre JP Bernard JS Lafontaine MJ Payan L Dahan N Pirro JF Seitz E Mas D Lombardo A Ouaissi 2008 High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas Ann Surg Oncol 15 8 2318 2328 18506539 10.1245/s10434-008-9940-z
14. W Weichert A Roske V Gekeler T Beckers MP Ebert M Pross M Dietel C Denkert C Rocken 2008 Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol 9 2 139 148 18207460 10.1016/S1470-2045(08)70004-4 1:CAS:528:DC%2BD1cXhsVOnu7c%3D
15. W Weichert A Roske S Niesporek A Noske AC Buckendahl M Dietel V Gekeler M Boehm T Beckers C Denkert 2008 Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo Clin Canc Res 14 6 1669 1677 10.1158/1078-0432.CCR-07-0990 1:CAS:528:DC%2BD1cXjtlejt7o%3D (Pubitemid 351469450)
16. T Rikimaru A Taketomi Y Yamashita K Shirabe T Hamatsu M Shimada Y Maehara 2007 Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma Oncology 72 1-2 69 74 18004079 10.1159/000111106 1:CAS:528:DC%2BD2sXhtlyksL3E (Pubitemid 350249132)
17. LJ Lesko AJ Atkinson Jr 2001 Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Annu Rev Pharmacol Toxicol 41 347 366 11264461 10.1146/annurev. pharmtox.41.1.347 1:CAS:528:DC%2BD3MXjsVaqtrs%3D (Pubitemid 32390116)
18. R Bakhtiar 2008 Biomarkers in drug discovery and development J Pharmacol Toxicol Meth 57 2 85 91 10.1016/j.vascn.2007.10.002 1:CAS:528: DC%2BD1cXjtlaqtbs%3D (Pubitemid 351384642)
19. JM Llovet AM Di Bisceglie J Bruix BS Kramer R Lencioni AX Zhu M Sherman M Schwartz M Lotze J Talwalkar GJ Gores 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Canc Inst 100 10 698 711 10.1093/jnci/djn134
20. T Amann U Maegdefrau A Hartmann A Agaimy J Marienhagen TS Weiss O Stoeltzing C Warnecke J Scholmerich PJ Oefner M Kreutz AK Bosserhoff C Hellerbrand 2009 GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis Am J Pathol 174 4 1544 1552 19286567 10.2353/ajpath.2009. 080596 1:CAS:528:DC%2BD1MXksVOrsrs%3D
21. C Hellerbrand T Amann J Schlegel P Wild F Bataille T Spruss A Hartmann AK Bosserhoff 2008 The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma Gut 57 2 243 251 17881540 10.1136/gut.2007.129544 1:CAS:528:DC%2BD1cXisVyjsLs%3D (Pubitemid 351158054)
22. A Tannapfel H Denk HP Dienes C Langner P Schirmacher M Trauner B Flott-Rahmel 2010 Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease Z Gastroenterol 48 4 486 498 20352596 10.1055/s-0029-1245278 1:STN:280:DC%2BC3c3islajtg%3D%3D
23. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours. Wiley-Blackwell
24. W Weichert C Denkert A Noske S Darb-Esfahani M Dietel SE Kalloger DG Huntsman M Kobel 2008 Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas Neoplasia 10 9 1021 1027 18714364 1:CAS:528:DC%2BD1cXht1Kgs7fI
25. K Miyake T Yoshizumi S Imura K Sugimoto E Batmunkh H Kanemura Y Morine M Shimada 2008 Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation Pancreas 36 3 e1 e9 18362831 10.1097/MPA.0b013e31815f2c2a 1:CAS:528:DC%2BD1cXkvVenur0%3D (Pubitemid 351440946)
26. A Lehmann C Denkert J Budczies AC Buckendahl S Darb-Esfahani A Noske BM Muller M Bahra P Neuhaus M Dietel G Kristiansen W Weichert 2009 High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo BMC Canc 9 395 10.1186/1471-2407-9-395
27. CA Krusche P Wulfing C Kersting A Vloet W Bocker L Kiesel HM Beier J Alfer 2005 Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis Breast Canc Res Treat 90 1 15 23 10.1007/s10549-004-1668-2 1:CAS:528:DC%2BD2MXit1Olur0%3D (Pubitemid 40486997)
28. KB Glaser J Li MJ Staver RQ Wei DH Albert SK Davidsen 2003 Role of class I and class II histone deacetylases in carcinoma cells using siRNA Biochem Biophys Res Commun 310 2 529 536 14521942 10.1016/j.bbrc.2003.09.043 1:CAS:528:DC%2BD3sXns1Krs7o%3D (Pubitemid 37163696)
29. H Fakhry T Miyamoto H Kashima A Suzuki H Ke I Konishi T Shiozawa 2010 Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells Hum Pathol 41 6 848 858 20178884 10.1016/j.humpath.2009.11.012 1:CAS:528:DC%2BC3cXmtFWksr4%3D
30. R Langer K Mutze K Becker M Feith K Ott H Hofler G Keller 2010 Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study J Clin Pathol 63 994 998 20924032 10.1136/jcp.2010.080952 1:CAS:528:DC%2BC3cXhs1SmtLzN
31. A Hrzenjak F Moinfar ML Kremser B Strohmeier PB Staber K Zatloukal H Denk 2006 Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells Mol Canc Ther 5 9 2203 2210 10.1158/1535-7163.MCT-05-0480 1:CAS:528:DC%2BD28Xps1yns7s%3D (Pubitemid 44530456)
32. BH Huang M Laban CH Leung L Lee CK Lee M Salto-Tellez GC Raju SC Hooi 2005 Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 Cell Death Differ 12 4 395 404 15665816 10.1038/sj.cdd.4401567 1:CAS:528:DC%2BD2MXitlCmsLs%3D (Pubitemid 40520691)